Join
Live feed
·
PRReleasevia Quantisnow
Ginkgo Bioworks Holdings Inc. logo

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ByQuantisnow·Wall Street's wire, on your screen.
DNA· Ginkgo Bioworks Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNA (Ginkgo Bioworks Holdings Inc.) and more on Quantisnow.